Tom 16, Nr 2 (2019)
Prewencja
Opublikowany online: 2019-06-27
Wyświetlenia strony
711
Wyświetlenia/pobrania artykułu
2056
Wiek naczyń — u kogo i jak go oceniać? Czy możemy „odmłodzić” naczynia naszych pacjentów?
Choroby Serca i Naczyń 2019;16(2):118-129.
Streszczenie
Kluczową rolę w prewencji chorób układu sercowo-naczyniowego (CVD) odgrywa ocena całkowitego ryzyka sercowo-naczyniowego. Po- zwala ona wyodrębnić pacjentów zagrożonych wystąpieniem CVD i zaplanować odpowiednie działania w celu ograniczenia lub eliminacji czynników ryzyka. Karta SCORE jest praktycznym narzędziem umożliwiającym oszacowanie 10-letniego ryzyka zgonu z powodu CVD. U młodych pacjentów, u których występują czynniki ryzyka, ryzyko bezwzględne wyliczone na pod- stawie karty SCORE może być jednak niskie mimo istotnie podwyższonego ryzyka względnego. W tej grupie chorych ocena tak zwanego wieku ryzyka sercowo-naczyniowego (inaczej: wieku serca, wieku naczyń) może być przydatna w identyfikacji osób, u których należy wdrożyć intensywne działania prewencyjne. Jednocześnie zastosowanie pojęcia „wiek ryzyka” ułatwia komunikację z pacjentem poprzez obrazowe przedstawienie mu oczekiwanego skrócenia długości życia w przypadku niepodjęcia działań prewencyjnych. Działania te powinny się koncentrować na ograniczeniu istniejących czynników ryzyka, co u części pacjentów będzie wymagać zastosowania farmakoterapii. Lekami o udowodnionej skuteczności w obniżaniu ryzyka CVD, tak- że w ramach prewencji pierwotnej, są statyny. Istotnie obniżają one stężenie lipoprotein o małej gęstości, które mają kluczowe znaczenie dla rozwoju miażdżycy. Jednocześnie leki te wyka- zują pozalipidowe działania plejotropowe, dzięki czemu mogą zahamować lub nawet częściowo odwrócić niekorzystne zmiany w obrębie ściany naczyń i doprowadzić do obniżenia wieku ryzyka sercowo-naczyniowego.
Słowa kluczowe: choroby układu sercowo-naczyniowegowiek ryzyka sercowo-naczyniowegomiażdżycaprewencja pierwotnastatynaatorwastatyna
Referencje
- Piepoli MF, Hoes AW, Agewall S, et al. Authors/Task Force Members:, Authors/Task Force Members, Additional Contributor: Simone Binno (Italy), Document Reviewers:, ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29): 2315–2381.
- Perk J, De Backer G, Gohlke H, et al. Comitato per Linee Guida Pratiche (CPG) dell'ESC, European Association for Cardiovascular Prevention & Rehabilitation (EACPR), Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice, European Association for Cardiovascular Prevention and Rehabilitation, European Association for Cardiovascular Prevention & Rehabilitation (EACPR), ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33(13): 1635–1701.
- Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr Pathol Mol Med. 2002; 21(2): 213–237.
- Conroy RM, Pyörälä K, Fitzgerald AP, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24(11): 987–1003.
- D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117(6): 743–753.
- Zdrojewski T, Jankowski P, Bandosz P, et al. [A new version of cardiovascular risk assessment system and risk charts calibrated for Polish population]. Kardiol Pol. 2015; 73(10): 958–961.
- The Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. The Lancet. 2014; 384(9943): 591–598.
- Wang JC, Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res. 2012; 111(2): 245–259.
- Spina M, Garbisa S, Hinnie J, et al. Age-related changes in composition and mechanical properties of the tunica media of the upper thoracic human aorta. Arteriosclerosis. 1983; 3(1): 64–76.
- Sun Z. Aging, arterial stiffness, and hypertension. Hypertension. 2015; 65(2): 252–256.
- Mitchell GF, Parise H, Benjamin EJ, et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004; 43(6): 1239–1245.
- Toprak A, Reddy J, Chen W, et al. Relation of pulse pressure and arterial stiffness to concentric left ventricular hypertrophy in young men (from the Bogalusa Heart Study). Am J Cardiol. 2009; 103(7): 978–984.
- Gradinaru D, Borsa C, Ionescu C, et al. Oxidized LDL and NO synthesis--Biomarkers of endothelial dysfunction and ageing. Mech Ageing Dev. 2015; 151: 101–113.
- Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990; 81(2): 491–497.
- Thijssen DHJ, Rongen GA, van Dijk A, et al. Enhanced endothelin-1-mediated leg vascular tone in healthy older subjects. J Appl Physiol (1985). 2007; 103(3): 852–857.
- Iantorno M, Campia U, Di Daniele N, et al. Obesity, inflammation and endothelial dysfunction. J Biol Regul Homeost Agents. 2014; 28(2): 169–176.
- Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014; 69 Suppl 1: S4–S9.
- Stamler JS, Hausladen A. Oxidative modifications in nitrosative stress. Nat Struct Biol. 1998; 5(4): 247–249.
- Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 2008; 5(6): 338–349.
- Li YSJ, Haga JH, Chien S. Molecular basis of the effects of shear stress on vascular endothelial cells. J Biomech. 2005; 38(10): 1949–1971.
- Wasilewski J, Kiljański T, Miszalski-Jamka K. [Role of shear stress and endothelial mechanotransduction in atherogenesis]. Kardiol Pol. 2011; 69(7): 717–720.
- Potter DR, van Teeffelen J, Vink H, et al. Perturbed mechanotransduction by endothelial surface glycocalyx modification greatly impairs the arteriogenic process. Am J Physiol Heart Circ Physiol. 2015; 309(4): H711–H717.
- Gradinaru D, Borsa C, Ionescu C, et al. Oxidized LDL and NO synthesis--Biomarkers of endothelial dysfunction and ageing. Mech Ageing Dev. 2015; 151: 101–113.
- Stein Y, Stein O. Does therapeutic intervention achieve slowing of progression or bona fide regression of atherosclerotic lesions? Arterioscler Thromb Vasc Biol. 2001; 21(2): 183–188.
- van Oostrom O, Velema E, Schoneveld AH, et al. Age-related changes in plaque composition: a study in patients suffering from carotid artery stenosis. Cardiovasc Pathol. 2005; 14(3): 126–134.
- Grufman H, Schiopu A, Edsfeldt A, et al. Evidence for altered inflammatory and repair responses in symptomatic carotid plaques from elderly patients. Atherosclerosis. 2014; 237(1): 177–182.
- O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999; 340(1): 14–22.
- Den Ruijter HM, Peters SAE, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA. 2012; 308(8): 796–803.
- Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 55(13): 1318–1327.
- Tinana A, Mintz GS, Weissman NJ. Volumetric intravascular ultrasound quantification of the amount of atherosclerosis and calcium in nonstenotic arterial segments. Am J Cardiol. 2002; 89(6): 757–760.
- Silber S. Comparison of spiral and electron beam tomography in the evaluation of coronary calcification in asymptomatic persons. Int J Cardiol. 2002; 82(3): 297–298; author reply 299.
- Catapano AL, Graham I, De Backer G, et al. Additional Contributor, Authors/Task Force Members:, ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37(39): 2999–3058.
- Szymański FM, Barylski M, Cybulska B, et al. Recommendation for the management of dyslipidemia in Poland - Third Declaration of Sopot. Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. Cardiol J. 2018; 25(6): 655–665.
- Zdrojewski T, Solnica B, Cybulska B, et al. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol. 2016; 74(3): 213–223.
- Ray KK, Cannon CP, McCabe CH, et al. PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005; 46(8): 1405–1410.
- Waters DD, Guyton JR, Herrington DM, et al. TNT Steering Committee Members and Investigators. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004; 93(2): 154–158.
- Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435): 685–696.
- Sever PS, Dahlöf B, Poulter NR, et al. ASCOT Investigators, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361(9364): 1149–1158.
- Yebyo HG, Aschmann HE, Kaufmann M, et al. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019; 210: 18–28.
- Mihaylova B, Emberson J, Blackwell L, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380(9841): 581–590.
- Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017; 120(1): 229–243.
- Hoshiga M, Arishiro K, Nakakoji T, et al. Switching to aggressive statin improves vascular endothelial function in patients with stable coronary artery disease. J Atheroscler Thromb. 2010; 17(7): 705–711.
- Yamada Y, Takeuchi S, Yoneda M, et al. Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome. Int J Cardiol. 2017; 240: 332–338.
- Schirmer SH, Werner CM, Laufs U, et al. Nitric oxide-donating statins: a new concept to boost the lipid-independent effects. Cardiovasc Res. 2012; 94(3): 395–397.
- Alber HF, Frick M, Süssenbacher A, et al. Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease. Wien Med Wochenschr. 2007; 157(3-4): 73–78.
- Kinlay S, Schwartz GG, Olsson AG, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003; 108(13): 1560–1566.
- Xu X, Liu Yu, Li K, et al. Intensive atorvastatin improves endothelial function and decreases ADP-induced platelet aggregation in patients with STEMI undergoing primary PCI: A single-center randomized controlled trial. Int J Cardiol. 2016; 222: 467–472.
